View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 16, 2020updated 11 Jul 2022 9:52am

Janssen begins second Phase III Covid-19 vaccine trial 

The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) has initiated enrolment and dosing of participants in the Phase III ENSEMBLE 2 trial of a two-dose regimen of JNJ-78436735, an investigational vaccine candidate for preventing Covid-19 infection.

The Janssen Pharmaceutical Companies of Johnson & Johnson (J&J) has initiated enrolment and dosing of participants in the Phase III ENSEMBLE 2 trial of a two-dose regimen of JNJ-78436735, an investigational vaccine candidate for preventing Covid-19 infection.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The ENSEMBLE 2 (NCT04614948) study, which is being conducted in collaboration with the UK National Institute for Health Research (NIHR), will enrol up to 30,000 participants globally.

This trial will run in parallel with the Phase III ENSEMBLE study of the single-dose regimen of JNJ-78436735 which is proceeding to enrol up to 60,000 participants across the globe.

For the study, participants will be enrolled in Belgium, Colombia, France, Germany, the Philippines, South Africa, Spain, the UK and US.

The randomised, double-blind, placebo-controlled ENSEMBLE 2 trial will analyse the safety and efficacy of a two-dose vaccine regimen versus placebo in adults with and without comorbidities associated with an increased risk for severe Covid-19.

It will analyse efficacy of the vaccine candidate after the first and second dose to evaluate the protection provided against the virus and possible incremental benefits for duration of protection with a second dose.

The initiation of the Phase III ENSEMBLE and ENSEMBLE 2 trials follow positive interim data from Janssen’s ongoing Phase I/IIa trial analysing the safety profile and immunogenicity of single-dose and two-dose regimen of the vaccine candidate.

As per the interim results, a single dose of the Covid-19 vaccine candidate induced a robust immune response and was shown to be well-tolerated.

In a separate development, J&J expanded partnership between its Janssen and the US Biomedical Advanced Research and Development Authority (BARDA) for the ongoing development of Janssen’s Covid-19 vaccine candidate.

As per the deal, Janssen will commit around $604m while BARDA will offer $454m to support the Phase III ENSEMBLE trial.

Johnson & Johnson executive committee vice-chairman and chief scientific officer Paul Stoffels said: “Combined with our own significant investment, this agreement has enabled our vital research and development and underscores the importance of public-private partnerships to tackle the worldwide Covid-19 pandemic.”

Last month, J&J temporarily paused dosing in all its vaccine candidate trials for Covid-19, including Phase III ENSEMBLE trial, after a study participant reported an unexplained illness.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology